JP2004002472A - 炎症性胃腸病の処置 - Google Patents
炎症性胃腸病の処置 Download PDFInfo
- Publication number
- JP2004002472A JP2004002472A JP2003303345A JP2003303345A JP2004002472A JP 2004002472 A JP2004002472 A JP 2004002472A JP 2003303345 A JP2003303345 A JP 2003303345A JP 2003303345 A JP2003303345 A JP 2003303345A JP 2004002472 A JP2004002472 A JP 2004002472A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- vla
- composition
- inflammatory bowel
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】 本発明の方法はVLA−4(すなわち大抵の種類の白血球で発現されて消化管における内皮および他の組織への白血球付着に関与する表面分子)を認識する抗体、ポリペプチドまたは他の分子を投与することからなっている。
【選択図】 なし
Description
結腸におけるVCAM−1発現
白血球付着に関与する内皮細胞表面蛋白質の発現に活性IBDが関係するかどうかを決定するため実験を行なった。IBD罹患者の結腸組織におけるVCAM−1の発現を正常もしくは無関係の結腸組織を対照に評価した。ヒト結腸鏡生検組織試料を患者の同意により得、OCTコンパウンド(ティシューテク社)に装着すると共にイソペンタン/液体窒素で急速凍結することにより凍結切片として作製した。ヒト結腸試料を正常結腸、活性の潰瘍性大腸炎結腸(UC−活性)、不活性の潰瘍性大腸炎結腸(UC−不活性)、無関係の潰瘍性大腸炎結腸(UC−無関係)、活性クローン氏病結腸(CD−活性)および無関係のクローン氏病結腸(CD−無関係)から得た。
これらデータは、たとえば上記非特許文献7や8により報告されたようなVCAM−1がIBDに関与する結腸組織と正常な結腸組織との両者にて発現されるという観察を確認する。CD組織およびUC組織の両者にて、VCAM−1は免疫細胞化学により試料の約60%で観察された。
CTT白血球の抗−VLA−4抗体認識
CTT白血球におけるエピトープを認識するかどうかを確認するため、抗−VLA−4モノクローナル抗体(HP1/2、バイオジェン・インコーポレーション社、ケンブリッジMAから入手)を試験した。
綿毛シシザルの試験
抗−VLA−4抗体、HP1/2(IgG1)の無菌塩水における保存溶液およびプラシーボ対照(塩水のみ)を自然の大腸炎の徴候(すなわち下痢など;上記マダラ等の文献参照)を示す10匹の綿毛シシザル(CTT)に投与すべく作製した。5匹のCTTにHP1/2を接種すると共に、残り5匹にはプラシーボを静脈内注射により接種した。毎日1mg HP1/2(すなわちCTTの体重約500gに対し約2mg/kg/1日)を8日間で(試験の0日、1日、2日、3日、4日、5日、6日、7日目)、CTTにHP1/2を注射した。各動物から結腸組織試料を1日おきに(試験の0日、2日、4日、6日、8日および10日目)生検した。
これらの結果は、抗−VLA−4抗体による処理が急性炎症指数における有意(p<0.01)の減少を与えたことを示す。
実施例3に記載した試験を14匹のCTTを用い、7匹にHP1/2を接種し、7匹にプラシーボを接種して繰り返した。0日目から10日目に至る急性炎症指数の変化を表3に示す。
この結果は、HP1/2を接種したCTTにおける急性炎症の有意の減少を示す。
Claims (21)
- 炎症性腸病に罹患した哺乳動物を処置するための医薬組成物の製造方法であって、Very Late Antigen−4(VLA−4)インテグリンのα4サブユニットのB1もしくはB2エピトープに結合する抗体を前記組成物の成分として含有させる工程を有する方法。
- 組成物を静脈内投与する請求項1に記載の方法。
- 抗−VLA−4抗体をHP1/2、HP2/1、HP2/4、L25およびP4C2よりなる群から選択する請求項1に記載の方法。
- 抗−VLA−4抗体がHP1/2またはVLA−4に結合しうるその断片である請求項1に記載の方法。
- 組成物を、炎症性腸病罹患者の体重に対し0.05〜5.0mg/kgの抗体を与えるような投与量にて投与する請求項1に記載の方法。
- 組成物を、炎症性腸病罹患者の体重に対し0.5〜2.0mg/kgの抗体を与えるような投与量にて投与する請求項5に記載の方法。
- 組成物を、哺乳動物において10〜15μg/mlの抗体の血漿レベルを与えるのに有効な量にて投与する請求項1に記載の方法。
- 哺乳動物が人間である請求項1に記載の方法。
- 哺乳動物が潰瘍性大腸炎の罹患者である請求項8に記載の方法。
- 哺乳動物がクローン氏病の罹患者である請求項8に記載の方法。
- 組成物を炎症性腸病の急性再発に際し投与する請求項1に記載の方法。
- 炎症性腸病に罹患した哺乳動物を処置するための医薬組成物の製造方法であって、哺乳動物を救助するのに有効な量の、Very Late Antigen−4(VLA−4)インテグリンのα4 サブユニットのB1もしくはB2に結合しうる抗体、組換抗体、キメラ抗体、これら抗体の断片、またはこれらの任意の組合せ物を前記組成物の成分として含有させる工程を有する方法。
- 抗体もしくは断片をモノクローナル抗体HP1/2;この種の抗体のFab、Fab′、F(ab′)2 もしくはF(V)断片から選択する請求項12に記載の方法。
- 組成物が複数の抗−VLA−4モノクローナル抗体またはそのVLA−4結合性断片からなる請求項12に記載の方法。
- 組成物が抗−VLA−4の他に抗−ELAM−1抗体、抗−ICAM−1抗体、抗−VCAM−1抗体、抗−CDX抗体、抗−LFA−1抗体、抗−CD18抗体またはこの種の抗体の組合せ物を含む請求項12に記載の方法。
- 抗−VLA−4抗体がHP1/2またはVLA−4に結合しうるその断片である請求項12に記載の方法。
- 組成物を、炎症性腸病罹患者の体重に対し0.05〜5.0mg/kgの抗体、抗体断片、ポリペプチドもしくは小分子を与えるような投与量にて投与する請求項12に記載の方法。
- 組成物を、炎症性腸病罹患者の体重に対し0.5〜2.0mg/kgの抗体、抗体断片、ポリペプチドもしくは小分子を与えるような投与量にて投与する請求項17に記載の方法。
- 組成物を、哺乳動物において10〜15μg/mlの抗体の血漿レベルを与えるのに有効な量にて投与する請求項12に記載の方法。
- 炎症性腸病を処置するための、実質的にVLA−4を認識するモノクローナル抗体を医薬上許容しうるキャリヤ中に含んでなる医薬組成物。
- 炎症性腸病に罹患した哺乳動物を処置するための医薬組成物の製造方法であって、抗−VLA−4抗体HP1/2またはVLA−4のα4 サブユニットのB1もしくはB2に結合しうるその断片を前記組成物の成分として含有させる工程を有する方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83513992A | 1992-02-12 | 1992-02-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5514148A Division JPH07506566A (ja) | 1992-02-12 | 1993-02-02 | 炎症性胃腸病の処置 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006306053A Division JP2007045843A (ja) | 1992-02-12 | 2006-11-10 | 炎症性胃腸病の処置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004002472A true JP2004002472A (ja) | 2004-01-08 |
JP4108572B2 JP4108572B2 (ja) | 2008-06-25 |
Family
ID=25268692
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5514148A Withdrawn JPH07506566A (ja) | 1992-02-12 | 1993-02-02 | 炎症性胃腸病の処置 |
JP2003303345A Expired - Lifetime JP4108572B2 (ja) | 1992-02-12 | 2003-08-27 | 炎症性胃腸病の処置 |
JP2006306053A Withdrawn JP2007045843A (ja) | 1992-02-12 | 2006-11-10 | 炎症性胃腸病の処置 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5514148A Withdrawn JPH07506566A (ja) | 1992-02-12 | 1993-02-02 | 炎症性胃腸病の処置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006306053A Withdrawn JP2007045843A (ja) | 1992-02-12 | 2006-11-10 | 炎症性胃腸病の処置 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0625912B1 (ja) |
JP (3) | JPH07506566A (ja) |
AT (1) | ATE151642T1 (ja) |
AU (1) | AU674302B2 (ja) |
CA (1) | CA2129637C (ja) |
DE (1) | DE69309906T2 (ja) |
DK (1) | DK0625912T3 (ja) |
ES (1) | ES2103468T3 (ja) |
GR (1) | GR3024041T3 (ja) |
HK (1) | HK1007683A1 (ja) |
WO (1) | WO1993015764A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
WO1994011027A1 (en) | 1992-11-13 | 1994-05-26 | Board Of Regents Of University Of Washington | Peripheralization of hematopoietic stem cells |
EP0682529B2 (en) * | 1993-02-09 | 2005-12-28 | Biogen Idec MA, Inc. | Antibody for the treatment of insulin dependent diabetes |
AU727187B2 (en) * | 1993-02-09 | 2000-12-07 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
ZA947006B (en) * | 1993-09-15 | 1995-05-02 | Univ Emory | Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions |
US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
DE69535133T2 (de) * | 1994-01-25 | 2008-08-21 | Elan Pharmaceuticals, Inc., San Francisco | Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4 |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19751251A1 (de) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
AU757873B2 (en) | 1998-09-14 | 2003-03-06 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
EP2289941A3 (en) | 2002-02-25 | 2012-01-18 | Elan Pharmaceuticals Inc. | Administration of agents for the treatment of inflammation |
EP1700850B1 (en) | 2003-12-22 | 2015-07-15 | Ajinomoto Co., Inc. | Phenylalanine derivative |
CA2714335A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
JP4652356B2 (ja) | 2007-02-26 | 2011-03-16 | アルプス電気株式会社 | ターンシグナルスイッチ装置 |
CN102057054B (zh) | 2008-04-11 | 2015-06-10 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
EP3466977B1 (en) | 2010-04-16 | 2022-01-05 | Biogen MA Inc. | Anti-vla-4 antibodies |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
WO2012151247A2 (en) | 2011-05-02 | 2012-11-08 | Millennium Pharmaceuticals, Inc. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
CN109884295B (zh) * | 2017-12-25 | 2022-03-08 | 苏州和锐生物科技有限公司 | 假单胞菌多肽、抗体捕获器件及试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0314863B1 (en) * | 1987-11-02 | 1994-12-07 | Baylor College Of Medicine | Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation |
US5147637A (en) * | 1988-06-07 | 1992-09-15 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
DK162890D0 (da) | 1990-07-06 | 1990-07-06 | Novo Nordisk As | Polypeptid |
CA2120500A1 (en) * | 1991-10-01 | 1993-04-15 | Mitsuaki Isobe | Preventing allograft rejection with antibodies to adhesion molecules |
-
1993
- 1993-02-02 CA CA002129637A patent/CA2129637C/en not_active Expired - Lifetime
- 1993-02-02 DE DE69309906T patent/DE69309906T2/de not_active Revoked
- 1993-02-02 WO PCT/US1993/000924 patent/WO1993015764A1/en not_active Application Discontinuation
- 1993-02-02 EP EP93904830A patent/EP0625912B1/en not_active Revoked
- 1993-02-02 DK DK93904830.2T patent/DK0625912T3/da active
- 1993-02-02 JP JP5514148A patent/JPH07506566A/ja not_active Withdrawn
- 1993-02-02 AU AU36059/93A patent/AU674302B2/en not_active Expired
- 1993-02-02 ES ES93904830T patent/ES2103468T3/es not_active Expired - Lifetime
- 1993-02-02 AT AT93904830T patent/ATE151642T1/de not_active IP Right Cessation
-
1997
- 1997-07-09 GR GR970401696T patent/GR3024041T3/el unknown
-
1998
- 1998-06-26 HK HK98106928A patent/HK1007683A1/xx not_active IP Right Cessation
-
2003
- 2003-08-27 JP JP2003303345A patent/JP4108572B2/ja not_active Expired - Lifetime
-
2006
- 2006-11-10 JP JP2006306053A patent/JP2007045843A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPH07506566A (ja) | 1995-07-20 |
DE69309906D1 (de) | 1997-05-22 |
ATE151642T1 (de) | 1997-05-15 |
CA2129637A1 (en) | 1993-08-19 |
JP4108572B2 (ja) | 2008-06-25 |
WO1993015764A1 (en) | 1993-08-19 |
EP0625912A1 (en) | 1994-11-30 |
GR3024041T3 (en) | 1997-10-31 |
CA2129637C (en) | 1999-05-04 |
JP2007045843A (ja) | 2007-02-22 |
HK1007683A1 (en) | 1999-04-23 |
ES2103468T3 (es) | 1997-09-16 |
AU3605993A (en) | 1993-09-03 |
AU674302B2 (en) | 1996-12-19 |
EP0625912B1 (en) | 1997-04-16 |
DK0625912T3 (da) | 1997-10-27 |
DE69309906T2 (de) | 1997-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4108572B2 (ja) | 炎症性胃腸病の処置 | |
US6482409B1 (en) | Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein | |
van Dinther-Janssen et al. | The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. | |
CA2561364C (en) | Steroid sparing agents and methods of using same | |
EP2248529B1 (en) | NKG2D antibodies for use in the treatment of autoimmune or inflammatory diseases | |
EP0528931B1 (en) | Humanized chimeric anti-icam-1 antibodies, methods of preparation and use | |
US8110189B2 (en) | T cell inhibitory receptor compositions and uses thereof | |
US7666417B2 (en) | Methods and compositions for treating autoimmune diseases or conditions | |
EP0289949A2 (en) | Intercellular adhesion molecules, and their binding ligands | |
NZ519447A (en) | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists | |
US5817311A (en) | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies | |
EP0606518B1 (en) | Intercellular adhesion molecules and their binding ligands | |
AU752710B2 (en) | Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway | |
AU629189B2 (en) | Intercellular adhesion molecules and their binding ligands | |
Azrin | The use of antibodies in clinical cardiology | |
AU636867B2 (en) | Rat monoclonal antibodies directed against human antigens and processes for preparation thereof | |
Pytowski et al. | A monoclonal antibody to a human neutrophil-specific plasma membrane antigen. Effect of the antibody on the C3bi-mediated adherence by neutrophils and expression of the antigen during myelopoiesis. | |
Kavanaugh | Antiadhesion therapy in rheumatoid arthritis: A review of recent progress | |
AU2011213878B2 (en) | Steroid sparing agents and methods of using same | |
WO1996035449A1 (en) | Monoclonal antibodies for the treatment of ulcerative colitis | |
EP0726942A1 (en) | Human foam cells and methods for preparing them, monoclonal antibodies to said foam cells and their pharmaceutical and diagnostic use | |
WO1992008489A1 (en) | Treatment for inflammatory bowel disease | |
IE83840B1 (en) | Intercellular adhesion molecules, and their binding ligands | |
IE19960275A1 (en) | Intercellular adhesion molecules, and their binding ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051201 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20051201 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20051201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060512 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060804 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061110 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070410 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070515 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20071019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080402 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110411 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120411 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120411 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130411 Year of fee payment: 5 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130411 Year of fee payment: 5 |